Functional antigenics

Nature Biotechnology

Volumn 16, Issue 3, 1998, Pages 305-307

  Persidis, Aris ^a  

^a Upstate Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN;

BIOTECHNOLOGY; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DRUG INDUSTRY; HISTORY; HUMAN; IMMUNOTHERAPY; LYMPHOCYTOTOXICITY; MAJOR HISTOCOMPATIBILITY COMPLEX; MEDICAL TECHNOLOGY; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY;

ANTIGENS; BIOTECHNOLOGY; DRUG DESIGN; HUMANS; MAJOR HISTOCOMPATIBILITY COMPLEX; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0031911676     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/nbt0398-305     Document Type: Short Survey

References (15)

1. Pharmaceutical Research Manufacturer's Association (PhRMA), 1997
2. Persidis, A. 1997. Nature Biotechnol. 15:1409-1411.
3. Such antigens are mostly peptides, but they can also be glycopeptides, lipopeptides, or other types of nonpeptide molecule.
4. Vose, B.M. and Bonnard G.D. 1982. Nature 296:359.
5. Murphy, G. et al. 1996. Prostate 29:371-380.
6. Kawakami, Y. et al. 1995. J. Immunol. 154:3961-3968.
7. Mayordomo, J.I. et al. 1995. Nat. Med. 1:1297-1302.
8. Vajda, S. and DeLisi, C. 1990. Biopolymers 29:1755.
9. Skipper, J.C.A. et al. 1996. J. Exp. Med. 183:527-534.
10. Meadows, L. et al. 1997. Immunity 6:273-281.
11. van der Bruggen, P. et al. 1991. Science 254:1643-1647.
12. Henderson, R.A. et al. 1993. Proc. Natl. Acad. Sci. USA 90:10275-10279.
13. Melief, C. et al. 1988. Ann. NY Acad. Sci. 532:280-291.
14. McCormack, A.L. et al. 1997. Anal. Chem. 69:767-776.
15. Evers, P. 1996. Immunotherapy: Current status and markets. Financial Times Management Reports.